These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
110 related items for PubMed ID: 9613981
1. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Dummer R, Geertsen R, Ludwig E, Niederer E, Burg G. Leuk Lymphoma; 1998 Feb; 28(5-6):515-22. PubMed ID: 9613981 [Abstract] [Full Text] [Related]
9. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome. Zaki MH, Shane RB, Geng Y, Showe LC, Everetts SE, Presky DH, Wysocka M, Moore JS, Rook AH. J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758 [Abstract] [Full Text] [Related]
10. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. Yoo EK, Cassin M, Lessin SR, Rook AH. J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181 [Abstract] [Full Text] [Related]
11. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH. J Immunol; 1999 Oct 01; 163(7):4073-9. PubMed ID: 10491012 [Abstract] [Full Text] [Related]
16. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Clin Diagn Lab Immunol; 1999 Jan 01; 6(1):79-84. PubMed ID: 9874668 [Abstract] [Full Text] [Related]
17. [Current pathogenetic aspects of Sézary syndrome and mycosis fungoides]. Dummer R, Willers J, Döbbeling U, Burg G. Hautarzt; 2001 Mar 01; 52(3):189-92. PubMed ID: 11284062 [Abstract] [Full Text] [Related]
20. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Steitz J, Roszkiewicz J, Bieber T, Tüting T. Clin Exp Dermatol; 2005 Nov 01; 30(6):702-6. PubMed ID: 16197392 [Abstract] [Full Text] [Related] Page: [Next] [New Search]